$12.82
0.39% day before yesterday
NYSE, Dec 27, 10:00 pm CET
ISIN
US6031701013
Symbol
MLYS
Sector
Industry

Mineralys Therapeutics Stock price

$12.82
-0.29 2.21% 1M
+1.32 11.48% 6M
+4.22 49.07% YTD
+4.48 53.72% 1Y
-5.62 30.48% 3Y
-5.62 30.48% 5Y
-5.62 30.48% 10Y
NYSE, Closing price Fri, Dec 27 2024
-0.05 0.39%
ISIN
US6031701013
Symbol
MLYS
Sector
Industry

Key metrics

Market capitalization $638.03m
Enterprise Value $374.43m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.69
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-168.35m
Free Cash Flow (TTM) Free Cash Flow $-128.55m
Cash position $263.60m
EPS (TTM) EPS $-3.27
P/E forward negative
Short interest 4.15%
Show more

Is Mineralys Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Mineralys Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Mineralys Therapeutics forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Mineralys Therapeutics forecast:

Buy
100%

Financial data from Mineralys Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.03 0.03
-
-
-0.03 -0.03
-
-
- Selling and Administrative Expenses 21 21
65% 65%
-
- Research and Development Expense 148 148
171% 171%
-
-168 -168
151% 151%
-
- Depreciation and Amortization 0.03 0.03
-
-
EBIT (Operating Income) EBIT -168 -168
151% 151%
-
Net Profit -153 -153
171% 171%
-

In millions USD.

Don't miss a Thing! We will send you all news about Mineralys Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mineralys Therapeutics Stock News

Neutral
Seeking Alpha
about 2 months ago
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore Richard Law - Goldman Sachs Annabel Samimy - Stifel Rami Katkhuda - Life...
Neutral
GlobeNewsWire
about 2 months ago
– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.
Neutral
GlobeNewsWire
about 2 months ago
RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in fireside chats at three upcoming investor conferences.
More Mineralys Therapeutics News

Company Profile

Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engaged in developing medicines to target disease, driven by abnormally elevated aldosterone. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Head office United States
CEO Jon Congleton
Employees 28
Founded 2019
Website www.mineralystx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today